ARTICLES BY THIS AUTHOR
- 9/25/2008
Catena for Friedreich's ataxia
Santhera Pharmaceuticals is introducing Catena for the symptomatic management of patients with Friedreich's ataxia, which is a rare, progressive neuromuscular disease. - 9/25/2008
Funding gap threatens future of pharmacies
Nadine Saby, president and CEO of CACDS, issues a wake up call about the future of pharmacy in Canada. - 9/25/2008
Managing statin-induced myalgia
Muscle symptoms are the most prevalent and important adverse effects associated with stain therapy, and often result in suboptimal adherence. - 9/23/2008
Tasigna for chronic myeloid leukemia
In October, Novartis expects to launch Tasigna for the treatment of chronic myeloid leukemia in adults who have developed resistance or intolerance to at least one prior therapy, including imatinib. - 9/18/2008
Xarelto: new oral anticoagulant
Bayer's Xarelto (rivaroxaban 10 mg tablets) is the second new oral anticoagulant to be marketed in Canada this year, following the introduction of Boehringer Ingelheim's Pradax (dabigatran etexilate 75 mg and 110 mg capsules) in July. - 9/17/2008
Managing milk protein allergy in infants
Cow's milk protein allergy is the most common form of milk protein allergy, occurring in 2-5% of formula-fed babies and 0.4-0.5% of breastfed babies. - 9/15/2008
Liberals promise catastrophic drug plan
- 9/10/2008
New Listeria guidelines